Innovative Targeted and Immune-Mediated Cancer Therapies
Pipeline
Developing first-in-class oral drug therapeutics with broad potential benefit for cancer patients
Science
Thoughtful exploration of new and validated pathways to discover and develop novel therapeutics
News
May 13,
2025
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
April 28,
2025
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
April 21,
2025
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
Events
Tuesday,
December 3RD,
2024
at
9:00 AM
Eastern
Piper Sandler 36th Annual Healthcare Conference
Listen: Webcast
Thursday,
June 20TH,
2024
at
8:30 AM
Eastern
Amezalpat (TPST-1120) Global Randomized Phase 1b/2 Combination Study Update Call
Listen: Webcast
Download: Presentation [pdf]
Wednesday,
October 11TH,
2023
at
8:30 AM
Eastern
TPST-1120 Global Randomized Phase 1b/2 Combination Study Data Call
Listen: Webcast
Download: Presentation [pdf]